SCHEMBL12096776

SCHEMBL12096776

COc1ccc(S(=O)(=O)n2c(Cc3ccc(C(=O)O)cc3)cc3cc(C(F)(F)F)ccc32)cc1

nearest known ligand 0.68

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ PPARG P37231 10/20 0.68
▸ PPARA Q07869 9/20 0.68
▸ PPARD Q03181 7/20 0.68
▸ RORC P51449 1/20 0.44
▸ TAS2R14 Q9NYV8 4/20 0.43
▸ TSHR P16473 1/20 0.43
▸ KDM4E B2RXH2 1/20 0.42
▸ TDP1 Q9NUW8 1/20 0.42
▸ USP2 O75604 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ POLB P06746 1/20 0.42
▸ GAA P10253 1/20 0.42
▸ HTT P42858 1/20 0.42
▸ MAPK10 P53779 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ SUV39H1 O43463 1/20 0.41
▸ EHMT2 Q96KQ7 1/20 0.41
▸ PRMT1 Q99873 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12096661 0.91 PPARG (0.68) PPARGPPARAPPARDRORC
SCHEMBL12096683 0.91 PPARG (0.55) PPARGPPARAPPARDRORC
SCHEMBL12096644 0.90 PPARG (0.70) PPARGPPARAPPARDRORCTAS2R14
SCHEMBL12097019 0.90 PPARG (0.55) PPARGPPARAPPARDRORC
SCHEMBL12096798 0.90 PPARG (0.54) PPARGPPARAPPARDRORC
SCHEMBL12096633 0.89 PPARG (0.55) PPARGPPARAPPARDRORCTAS2R14
SCHEMBL12096709 0.89 PPARG (0.54) PPARGPPARAPPARDRORC
SCHEMBL12096684 0.89 PPARG (0.55) PPARGPPARAPPARDRORCLMNA
SCHEMBL12097016 0.88 PPARG (0.55) PPARGPPARAPPARDRORC
SCHEMBL12096911 0.88 PPARG (0.67) PPARGPPARAPPARDRORC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease LABORATOIRES FOURNIER SA (FR) 2012-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120232070-A1 Use of Indole Derivatives as Nurr-1 Activators for the Application Thereof as a Medicament for the Treatment of Parkinson's Disease NCOR1, NR0B1, MTNR1A PPARG 423/4885PPARA 564/4885PPARD 302/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback